"
Combination of Aromatase Inhibitors with Metronomic Capecitabine: A New Chemoendocrine Treatment for Advanced Breast Cancer"
written by Wei Shi, Xinyue Wang, Xiwen Bi, Wen Xia, Jiajia Huang, Yanhong Su, Zhangzan Huang, Zhongyu Yuan,
published by
Journal of Cancer Therapy,
Vol.10 No.2, 2019
has been cited by the following article(s):
[1]
|
Capecitabine Plus Aromatase Inhibitor as First Line Therapy for Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer
Current Oncology,
2023
DOI:10.3390/curroncol30070454
|
|
|
[2]
|
Mutual exclusivity of ESR1 and TP53 mutations in endocrine resistant metastatic breast cancer
npj Breast Cancer,
2022
DOI:10.1038/s41523-022-00426-w
|
|
|
[3]
|
Metronomic chemotherapy combined with endocrine therapy: are we challenging some dogmas?
Expert Review of Anticancer Therapy,
2020
DOI:10.1080/14737140.2020.1782200
|
|
|
[4]
|
Metronomic capecitabine with aromatase inhibitors for patients with metastatic hormone-receptor positive, HER2-negative breast cancer
Breast Cancer Management,
2019
DOI:10.2217/bmt-2019-0012
|
|
|